Division of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor.
Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor.
JAMA Cardiol. 2019 Apr 1;4(4):353-362. doi: 10.1001/jamacardio.2019.0375.
IMPORTANCE: Cardiovascular disease (CVD) is a leading cause of death among patients with end-stage renal disease (ESRD). Young adult (ages 22-29 years) have risks for ESRD-associated CVD that may vary from other ages. OBJECTIVE: To test the hypothesis that young adult-onset ESRD is associated with higher cardiovascular (CV) hospitalizations and mortality with different characteristics than childhood-onset disease. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used the US Renal Data System to categorize patients who initiated ESRD care between 2003 and 2013 by age at ESRD onset (1-11, 12-21, and 22-29 years). Cardiovascular hospitalizations were identified via International Classification of Diseases, Ninth Revision discharge codes and CV mortality from the Centers for Medicare & Medicaid ESRD Death Notification Form. Patients were censored at death from non-CVD events, loss to follow-up, recovery, or survival to December 31, 2014. Adjusted proportional hazard models (95% CI) were fit to determine risk of CV hospitalization and mortality by age group. Data analysis occurred from May 2016 and December 2017. EXPOSURES: Onset of ESRD. MAIN OUTCOMES AND MEASURES: Cardiovascular mortality and hospitalization. RESULTS: A total of 33 156 patients aged 1 to 29 years were included in the study population. Young adults (aged 22-29 years) had a 1-year CV hospitalization rate of 138 (95% CI, 121-159) per 1000 patient-years. Young adults had a higher risk for CV hospitalization than children (aged 1-11 years; hazard ratio [HR], 0.41 [95% CI, 0.26-0.64]) and adolescents (aged 12-21 years; HR, 0.86 [95% CI, 0.77-0.97]). Of 4038 deaths in young adults, 1577 (39.1%) were owing to CVD. Five-year cumulative incidence of mortality in this group (7.3%) was higher than in younger patients (adolescents, 4.0%; children, 1.7%). Adjusted HRs for CV mortality were higher for young adults with all causes of ESRD than children (cystic, hereditary, and congenital conditions: HR, 0.22 [95% CI, 0.11-0.46]; P < .001; glomerulonephritis: HR, 0.21 [95% CI, 0.10-0.44]; P < .001; other conditions: HR, 0.33 [95% CI, 0.23-0.49]; P < .001). Adolescents had a lower risk for CV mortality than young adults for all causes of ESRD except glomerulonephritis (cystic, hereditary, and congenital conditions: HR, 0.45 [95% CI, 0.27-0.74]; glomerulonephritis: HR, 0.99 [95% CI, 0.76-1.11]; other: HR, 0.47 [95% CI, 0.40-0.57]). Higher risks for CV hospitalization and mortality were associated with lack of preemptive transplant compared with hemodialysis (hospital: HR, 14.24 [95% CI, 5.92-34.28]; mortality: HR, 13.64 [95% CI, 8.79-21.14]) and peritoneal dialysis [hospital: HR, 8.47 [95% CI, 3.50-20.53]; mortality: HR, 7.86 [95% CI, 4.96-12.45]). Nephrology care before ESRD was associated with lower risk for CV mortality (HR, 0.77 [95% CI, 0.70-0.85]). CONCLUSIONS AND RELEVANCE: Cardiovascular disease accounted for nearly 40% of deaths in young adults with incident ESRD in this cohort. Identified risk factors may inform development of age-appropriate ESRD strategies to improve the CV health of this population.
重要性:心血管疾病(CVD)是终末期肾病(ESRD)患者死亡的主要原因。年轻成人(22-29 岁)发生与 ESRD 相关的 CVD 的风险可能与其他年龄段不同。
目的:检验年轻成人起病的 ESRD 与儿童起病的疾病相比,心血管(CV)住院和死亡率的假设,其特征不同。
设计、地点和参与者:本基于人群的队列研究使用美国肾脏数据系统(US Renal Data System),根据 ESRD 发病时的年龄(1-11、12-21 和 22-29 岁)将 2003 年至 2013 年开始 ESRD 治疗的患者分为三组。通过国际疾病分类第 9 版出院代码和医疗保险和医疗补助服务中心(Centers for Medicare & Medicaid)的 ESRD 死亡通知表确定 CV 住院和 CV 死亡率。患者在非 CVD 事件、失访、康复或 2014 年 12 月 31 日之前存活的情况下死亡被视为删失。使用调整后的比例风险模型(95%CI)确定按年龄组的 CV 住院和死亡率风险。数据分析于 2016 年 5 月至 2017 年 12 月进行。
暴露:ESRD 发病。
主要结局和措施:CV 死亡率和住院率。
结果:共纳入了 33156 名年龄在 1 至 29 岁的患者。年轻成年人(22-29 岁)的 1 年 CV 住院率为每 1000 名患者年 138(95%CI,121-159)例。与儿童(1-11 岁)相比,年轻成年人的 CV 住院风险更高(风险比[HR],0.41 [95%CI,0.26-0.64])和青少年(12-21 岁)(HR,0.86 [95%CI,0.77-0.97])。在年轻成年人中,有 4038 例死亡,其中 1577 例(39.1%)归因于 CVD。该组的 5 年累积死亡率(7.3%)高于年轻患者(青少年为 4.0%;儿童为 1.7%)。与儿童相比,所有原因导致的 ESRD 的年轻成年人的 CV 死亡率调整后的 HR 更高(囊性、遗传性和先天性疾病:HR,0.22 [95%CI,0.11-0.46];P<.001;肾小球肾炎:HR,0.21 [95%CI,0.10-0.44];P<.001;其他疾病:HR,0.33 [95%CI,0.23-0.49];P<.001)。除了肾小球肾炎(囊性、遗传性和先天性疾病:HR,0.45 [95%CI,0.27-0.74];肾小球肾炎:HR,0.99 [95%CI,0.76-1.11];其他疾病:HR,0.47 [95%CI,0.40-0.57])外,所有原因导致的 ESRD 的青少年的 CV 死亡率风险均低于年轻成年人。与血液透析(住院:HR,14.24 [95%CI,5.92-34.28];死亡率:HR,13.64 [95%CI,8.79-21.14])和腹膜透析(住院:HR,8.47 [95%CI,3.50-20.53];死亡率:HR,7.86 [95%CI,4.96-12.45])相比,缺乏预先移植与 CV 住院和死亡率的风险增加相关。在 ESRD 之前接受肾病治疗与 CV 死亡率降低相关(HR,0.77 [95%CI,0.70-0.85])。
结论和相关性:在该队列中,年轻成人起病的 ESRD 患者中,近 40%的死亡归因于 CVD。确定的危险因素可能为制定适合年龄的 ESRD 策略提供信息,以改善该人群的 CV 健康状况。
Nephrol Ther. 2013-9
JAMA Intern Med. 2019-4-1
Am J Nephrol. 2018-5-18
Am J Nephrol. 2015
Am J Kidney Dis. 2018-10-11
Arthritis Care Res (Hoboken). 2015-10
Front Endocrinol (Lausanne). 2025-8-13
Medicine (Baltimore). 2025-5-16
BMC Nephrol. 2025-4-5
Front Med (Lausanne). 2025-3-17
J Am Soc Nephrol. 2019-1-17
N Engl J Med. 2018-12-26
J Am Soc Nephrol. 2017-5
Natl Vital Stat Rep. 2016-6